March 29, 2022 | Featured on the European Biopharmaceutical Review
CAMBRIDGE, Tuesday 29 March 2022 — bit.bio featured in April 2022 Issue of European Biopharmaceutical Review (EBR).
The evolving obstacles of working with stem cell derived cells continues to pose question marks for the biopharma industry. In this article, leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.
The expert panel included: Dr Davide Danovi, Senior Lecturer at King’s College London and Director of Cellular Phenotyping at bit.bio; Dr Deepak Srivastava, Reader in Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders, King’s College London & Director, Wohl Cellular Imaging Centre; and Dr Ivo Lieberam, Senior Lecturer, Centre for Stem Cells and Regenerative Medicine, King’s College London. Their insights, summarised in the issue, cover three main challenges associated with cell models: suitability; scalability; and consistency and reproducibility.
Access the full article here on page 38-40.